Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agilent Technologies, University of Rouen and A*STAR’s Bioprocessing Technology Institute Collaborate

Published: Thursday, May 23, 2013
Last Updated: Thursday, May 23, 2013
Bookmark and Share
Organisations will work together to further innovation in biopharmaceuticals and glycomics.

Agilent Technologies Inc., the Glyco-MEV laboratory at the University of Rouen, in France, and the Bioprocessing Technology Institute at the Agency for Science, Technology and Research (A*STAR), in Singapore, have signed a memorandum of understanding to work together in order to develop tools to effectively analyze biologics and vaccines.

Biologics are molecules such as antibodies and other recombinant protein-based therapeutics. Used in combination with vaccines, they can prevent or treat a variety of serious medical conditions such as cancers, immune disorders and infectious diseases that affect millions of people annually. These therapeutic agents are typically produced by bioprocesses using living cells as factories for their production.

Unlike small molecule drugs, biologics produced by cells are typically more heterogeneous in structure, most notably in glycosylation, which is the modification of protein drugs by sugars (also known as glycans). Sugars are known to prolong the half-life of biologic drugs and thereby reduce the frequency and dosage of drugs given to human patients.

A*STAR’s Bioprocessing Technology Institute will join forces with the University of Rouen’s Glyco-MEV laboratory and Agilent to develop innovative analytical techniques to ensure that these biologics are safe and effective. BTI is currently working to develop methods of producing and analyzing these biologics in animal cells while Glyco-MEV laboratory specializes in the production of those molecules in plant systems.

This strategic partnership strengthens the collaboration between BTI and Glyco-MEV laboratory and is enhanced by Agilent’s technological expertise to develop new, sensitive and high-throughput methodologies that are particularly adapted to the analysis of biopharmaceuticals. In addition, the Glyco-MEV laboratory will be Agilent’s glycomics reference site in Europe, and BTI will be its glycomics reference site for Southeast Asia.

Professor Lam Kong Peng, executive director of BTI, said, “With increasing use of biologics to treat human diseases and with more biosimilars coming to market in the next few years, it is timely for BTI to develop novel technologies that would improve the characterization and analysis of protein-based drugs. This collaboration would enhance Singapore’s reputation as a world-class destination for biologics manufacturing and R&D.”

“This collaboration will enhance our international expertise with regards to the glycan analysis and engineering of biopharmaceuticals produced in plant and microalgae cells,” said Prof Patrice Lerouge, director of the Glyco-MEV laboratory. “We also hope that such a research initiative will facilitate exchanges of lab members and PhD students between Singapore and France.”

“This research initiative enables scientists to optimize glycan analytical workflows on the Agilent HPLC-Chip/MS system,” said Dr. Rudolf Grimm, Agilent’s director of science and technology and manager of collaborations in the Asia-Pacific region. “We look forward to working with these leading organizations to drive discovery in this important field.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Extends Agreement with PerkinElmer on Bioanalyzer Chips
PerkinElmer supplies chips for Agilent's popular 2100 Bioanalyzer system.
Thursday, January 21, 2016
Agilent, Singapore Institute Collaborate
Agilent Technologies and Singapore's Bioprocessing Technology Institute today announced a collaboration to develop new analytical approaches to specific protein-linked sugar compounds.
Wednesday, July 15, 2015
Agilent Collaborate with A*STAR’s Bioprocessing Technology Institute
Collaboration addresses a critical need in the biopharmaceutical industry.
Tuesday, July 14, 2015
Utilizing Fast HPLC Screening Methods for the Detection of Steroids
Analysis of steroids improved by choosing the optimal HPLC column for the separation.
Saturday, January 17, 2015
How to Achieve High-Speed, High-Resolution Glycan Mapping for mAb Characterization
The full characterization of biotherapeutics is required by regulatory authorities as properties such as safety, efficacy and the serum half-life of therapeutic proteins can be affected by differences in their glycosylation pattern.
Monday, December 22, 2014
Agilent Supports Inaugural Singapore-South Korea Symposium on Glycomics
Event follows collaboration to develop tools for analysis of biologics, vaccines.
Saturday, February 15, 2014
Agilent Announces Agreement with Picometrics Technologies
Agilent to provide Picometrics' biopharmaceutical customers with combined solutions for capillary electrophoresis (CE), laser induced fluorescence (LIF) detection and mass spectrometry.
Friday, January 17, 2014
Agilent, University of Rouen and A*STAR’s Bioprocessing Technology Institute to Collaborate
The collaborations aims to further innovation in biopharmaceuticals and glycomics through developing tools to effectively analyze biologics and vaccines.
Thursday, May 23, 2013
Agilent Technologies Introduces Verified Dissolution Components for Pharmaceutical Market
Agilent Technologies Inc. introduced a new series of verified dissolution components, including molded vessels as well as paddle and basket shafts.
Wednesday, May 15, 2013
Dako to Offer New Antibody in U.S. to Diagnose Breast Cancer
Dako receives clearance to sell FLEX Monoclonal Rabbit Anti-Human Estrogen Receptor a, Clone EP1 in US.
Monday, April 08, 2013
Agilent Technologies and Chungnam National University Announce Glycomics Research Initiatives
The collaboration hopes to develop biomarkers and new therapeutic antibodies to combat diseases such as cancer.
Tuesday, April 02, 2013
Merck-Serono Adopts Agilent Technologies’ Electronic Lab Notebook for Biology Research
Agilent Technologies Inc. have announced that Merck-Serono, a division of Merck KGaA, Darmstadt, Germany, has selected the Agilent OpenLAB Electronic Lab Notebook (ELN) to enhance scientific collaboration globally throughout R&D for finding new small molecules and biopharmaceuticals.
Tuesday, November 23, 2010
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Antibody Drug Shows Promise in HIV Treatment
Researchers are a step closer to an alternative HIV treatment that has the potential for lasting effects and less frequent dosing.
Flu Vaccine May Reduce Risk of Death For Type 2 Diabetes Patients
Researchers at Imperial College London have suggested that the vaccine may have substantial benefits for patients with long-term conditions.
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Vaccine Strategy Targets Multiple Influenza Viruses
Scientists have identified vaccine-induced antibodies that can neutralize strains of influenza virus that infect humans.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!